SiBone (NASDAQ:SIBN) Director Jeffrey Dunn Sells 20,000 Shares of Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $18.91, for a total value of $378,200.00. Following the sale, the director owned 16,057 shares in the company, valued at $303,637.87. The trade was a 55.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

SiBone Stock Performance

SIBN stock traded down $0.52 during trading on Thursday, hitting $18.64. 632,446 shares of the company’s stock traded hands, compared to its average volume of 500,274. The stock has a market capitalization of $826.68 million, a price-to-earnings ratio of -54.82 and a beta of 0.70. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The stock has a fifty day moving average price of $18.09 and a two-hundred day moving average price of $15.55. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million during the quarter, compared to analyst estimates of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, equities analysts anticipate that SiBone will post -0.4 EPS for the current fiscal year.

Institutional Trading of SiBone

Several large investors have recently added to or reduced their stakes in SIBN. First Light Asset Management LLC lifted its stake in SiBone by 162.4% in the 4th quarter. First Light Asset Management LLC now owns 5,032,904 shares of the company’s stock worth $99,249,000 after acquiring an additional 3,115,001 shares in the last quarter. Granahan Investment Management LLC increased its holdings in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after purchasing an additional 858,942 shares during the period. California State Teachers Retirement System lifted its position in shares of SiBone by 1,751.6% in the second quarter. California State Teachers Retirement System now owns 726,942 shares of the company’s stock worth $11,864,000 after purchasing an additional 687,681 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its holdings in shares of SiBone by 113.3% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock worth $14,228,000 after purchasing an additional 598,300 shares during the period. Finally, Cadian Capital Management LP increased its stake in SiBone by 96.8% in the 4th quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock valued at $23,094,000 after buying an additional 576,100 shares during the period. 98.11% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SIBN has been the subject of a number of research reports. Truist Financial restated a “buy” rating and set a $23.00 target price (up from $21.00) on shares of SiBone in a report on Tuesday, August 4th. UBS Group lifted their target price on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Finally, TD Cowen lifted their price target on SiBone from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $24.17.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.